Lessons learned from COVID-19: The way we develop new medicines is changing
By Richard Moscicki, M.D. | February 10, 2021
The COVID-19 pandemic has affected nearly every aspect of society, including the way scientists conduct the testing of medicines.
Read More
2020 FDA approvals show innovation despite COVID-19 pandemic challenges
By Andrew Powaleny | January 26, 2021
A new report from the U.S. Food and Drug Administration (FDA) notes that the Center for Drug Evaluation and Research (CDER) approved 53 novel drugs last year. These figures are in addition to...
Read More
ICYMI: Cancer death rate continues decline due to advances in treatment
By Andrew Powaleny | January 19, 2021
For the second year in a row, The American Cancer Society (ACS) reports a record single-year decline in cancer death rates in the United States. Each year, ACS estimates the number of new cancer...
Read More
Report: More than 1,300 medicines and vaccines in development to help fight cancer
By Andrew Powaleny | December 15, 2020
Over the last 30 years, significant progress has been made in the fight against cancer. Researchers have expanded their understanding of how cancer develops and how to target medicines for...
Read More
Flu Season 2020: Why it’s time to talk to your doctor today about getting a flu shot
By Richard Moscicki, M.D. | October 8, 2020
As America’s biopharmaceutical companies work around the clock to combat COVID-19, another virus with deadly consequences is right around the corner. The COVID-19 pandemic has led to more than 7.5...
Read More
New Graphic: Public-Private collaboration fuels the U.S. biopharmaceutical ecosystem
By Jocelyn Ulrich | September 16, 2020
America’s biopharmaceutical companies are at the heart of a robust research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world. In recent...
Read More
R&D Focus: 5 things to know about the biopharmaceutical research ecosystem
By Jocelyn Ulrich | July 13, 2020
America’s biopharmaceutical companies are at the heart of a robust research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world. In recent...
Read More
What scientific experts are saying about vaccine safety
By Andrew Powaleny | June 4, 2020
Vaccines have played a critical role in reducing the spread of, and in some cases, eliminating the threat of many devastating infectious diseases. They are often cited as second only to clean...
Read More
R&D Focus: New report shows nearly 600 medicines in development for pediatric patients
By Andrew Powaleny | February 13, 2020
America’s biopharmaceutical researchers are committed to studying, developing and testing medicines to meet the unique needs of pediatric patients. New treatment options for infants, children and...
Read More
ICYMI: 2019 brings innovative medicines to patients
By Andrew Powaleny | January 17, 2020
New reports from the U.S. Food and Drug Administration (FDA) show a total of 55 novel new medicines were approved in 2019. Among these, 48 were approved by the Center for Drug Evaluation and...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
